Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …

Objective: For patients with locally advanced and unresectable pancreatic cancer (PDAC),
neodadjuvant treatment and consecutive surgical exploration have been studied during the …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Background In metastatic disease (M1), chemotherapy (expected survival: 6–10 months) is
considered the only treatment option. The aim of this study was to evaluate the outcome of …

Background: Modifications of FOLFIRINOX are widely used despite the absence of
prospective data validating efficacy in metastatic disease (metastatic pancreatic cancer …

Purpose Although surgery is the standard of care for resectable pancreatic cancer (PC),
standard-dose chemoradiation therapy and chemotherapy alone are suitable for patients …

Purpose To describe safety and effectiveness of percutaneous irreversible electroporation
(IRE) for treatment of unresectable, locally advanced pancreatic adenocarcinoma (LAPC) …

Simple Summary Pancreatic cancer is the fourth leading cause of cancer-related mortality
worldwide. The poor survival associated with this disease is due to delayed diagnosis, a …

Background Outcomes of neoadjuvant systemic therapy versus an upfront operation for
clinical, stage III pancreatic adenocarcinoma remain poorly defined. Our aim was to …